Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business, Basis of Presentation, Merger with NovellusDx, Ltd., Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements - Acquisition (Details)

v3.10.0.1
Organization, Description of Business, Basis of Presentation, Merger with NovellusDx, Ltd., Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements - Acquisition (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Aug. 15, 2017
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]            
Goodwill   $ 17,257   $ 17,257   $ 17,992
Business Acquisition, Pro Forma Information [Abstract]            
Revenue   5,940 $ 8,028 20,643 $ 21,598  
Net (loss)   (8,519) (633) (16,608) (12,979)  
VivoPharm            
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]            
Purchase of outstanding stock $ 1,600          
Business combination, consideration transferred, equity issued value $ 8,100          
Business combination, consideration transferred, percentage withheld in escrow 20.00%          
Business combination, consideration transferred, expiration period 12 months          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]            
Cash $ 544          
Accounts receivable 905          
Lab supplies 350          
Prepaid expenses and other current assets 60          
Fixed assets 765          
Intangible assets 3,160          
Goodwill 5,960          
Accounts payable and accrued expenses (913)          
Deferred revenue (814)          
Deferred rent and other (222)          
Obligations under capital leases (76)          
Total purchase price $ 9,719          
Business Acquisition, Pro Forma Information [Abstract]            
Revenue     9,069   25,335  
Net loss     $ (976)   $ (13,788)  
Basic net loss per share (in dollars per share)     $ (0.04)   $ (0.61)  
Dilutive net loss per share (in dollars per share)     $ (0.16)   $ (0.61)  
Refinement in contract completion estimate   200        
Revenue   535   3,243    
Net (loss)     $ 380   $ 380  
Biopharma Services            
Business Acquisition, Pro Forma Information [Abstract]            
Revenue   3,850 4,168 11,099 11,175  
Discovery Services            
Business Acquisition, Pro Forma Information [Abstract]            
Revenue   $ 535 980 $ 3,525 1,536  
Discovery Services | VivoPharm            
Business Acquisition, Pro Forma Information [Abstract]            
Revenue     $ 794   $ 794